We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.89%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.02B
AUM Growth
+$60.4M
Cap. Flow
-$61.1M
Cap. Flow %
-5.98%
Top 10 Hldgs %
49.68%
Holding
183
New
37
Increased
35
Reduced
45
Closed
53

Top Buys

Rank Stock Value
1
BCOM
B Communications Ltd
BCOM
+$95.7M
2
BIIB icon
Biogen
BIIB
+$20.4M
3
CELG
Celgene Corp
CELG
+$10.3M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$7.22M
5
ATXS
Astria Therapeutics
ATXS
+$5.62M

Top Sells

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$18.8M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.9M
3
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$12.5M
4
AMGN icon
Amgen
AMGN
+$9.61M
5
IWM icon
iShares Russell 2000 ETF
IWM
+$6.98M

Sector Composition

Rank Sector Weight
1 Healthcare 50.75%
2 Technology 3.95%
3 Utilities 1.35%
4 Industrials 0.96%
5 Consumer Discretionary 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
26
DELISTED
Seagen Inc. Common Stock
SGEN
$6.78M 0.66%
140,000
-60,000
-30% -$2.48M
BMY icon
27
Bristol-Myers Squibb
BMY
$133B
$6.65M 0.65%
100,000
– –
ALDR
28
DELISTED
Alder Biopharmaceuticals
ALDR
$6.62M 0.65%
125,000
-25,000
-17% -$909K
VNDA icon
29
Vanda Pharmaceuticals
VNDA
$307M
$6.51M 0.64%
513,390
-30,000
-6% -$324K
BCOM
30
DELISTED
B Communications Ltd
BCOM
$6.45M 0.63%
+5,977,000
New +$95.7M
FOLD
31
DELISTED
Amicus Therapeutics
FOLD
$6.37M 0.62%
450,000
– –
AMAG
32
DELISTED
AMAG Pharmaceuticals
AMAG
$6.23M 0.61%
90,230
-110,000
-55% -$6.92M
PRTA icon
33
Prothena Corp
PRTA
$425M
$6.06M 0.59%
115,133
+27,000
+31% +$1.07M
ARRY
34
DELISTED
Array Biopharma Inc
ARRY
$5.77M 0.57%
800,000
-123,922
-13% -$914K
FWP
35
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$5.71M 0.56%
21,429
-4,285
-17% -$1.03M
EWG icon
36
iShares MSCI Germany ETF
EWG
$1.59B
$5.37M 0.53%
192,630
+84,630
+78% +$2.51M
GWPH
37
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.34M 0.52%
43,500
+8,500
+24% +$964K
CYNA
38
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$5.32M 0.52%
+316,448
New +$5.19M
INSM icon
39
Insmed
INSM
$21.4B
$5.25M 0.51%
215,000
-35,000
-14% -$795K
MDCO
40
DELISTED
Medicines Co
MDCO
$5.15M 0.5%
180,000
+80,000
+80% +$2.23M
TSRO
41
DELISTED
TESARO, Inc.
TSRO
$5.14M 0.5%
+87,500
New +$5.02M
ATXS
42
DELISTED
Astria Therapeutics
ATXS
$5.06M 0.5%
+7,434
New +$5.62M
UTHR icon
43
United Therapeutics
UTHR
$25.8B
$5.02M 0.49%
28,840
-20,000
-41% -$3.6M
ACOR
44
DELISTED
Acorda Therapeutics
ACOR
$5M 0.49%
+1,250
New +$4.83M
CPRX
45
DELISTED
Catalyst Pharmaceutical
CPRX
$4.96M 0.49%
1,200,000
+100,000
+9% +$399K
BLCM
46
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$4.92M 0.48%
23,151
-1,806
-7% -$443K
RARE icon
47
Ultragenyx Pharmaceutical
RARE
$2.45B
$4.88M 0.48%
+47,700
New +$3.7M
SRPT icon
48
Sarepta Therapeutics
SRPT
$1.57B
$4.57M 0.45%
+150,000
New +$3.07M
APTV icon
49
Aptiv
APTV
$12B
$4.52M 0.44%
+53,070
New +$4.54M
ORBK
50
DELISTED
Orbotech Ltd
ORBK
$4.47M 0.44%
214,922
+18,300
+9% +$354K
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sphera Funds Management held 183 positions worth $1.02B, up 6.3% from $961M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sphera Funds Management withdrew a net $61.1M in Q2 2015, closing 53 positions and reducing 45 holdings. Its most notable exit was Endo International plc, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 54% a quarter earlier, followed by Technology and Utilities.

Against the trend, Sphera Funds Management opened a new position in B Communications Ltd worth $6.45M.

  • Sphera Funds Management's largest Q2 2015 buy was B Communications Ltd: 5,977,000 shares worth $6.45M.
  • Sphera Funds Management added most to Biogen in Q2 2015, an estimated $20.4M increase.
  • Sphera Funds Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $13.9M.
  • Sphera Funds Management fully exited Endo International plc in Q2 2015, selling an estimated $18.8M.
  • Sphera Funds Management's ten largest holdings make up 50% of its $1.02B portfolio in Q2 2015.
  • Sphera Funds Management opened 37 new positions and closed 53 in Q2 2015.
  • Sphera Funds Management's portfolio value rose 6.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q2 2015, filed 6 Aug 2015.